StreetInsider.com News Articles

Form 8-K Tvardi Therapeutics, For: Jul 17

Fri, 17 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260717/26784403.html

Form 8-K Tvardi Therapeutics, For: Jul 17

Fri, 17 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260717/26784403.html

Form 424B5 Tvardi Therapeutics,

Fri, 17 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260717/26784354.html

Form 424B5 Tvardi Therapeutics,

Fri, 17 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260717/26784354.html

Piper Sandler Upgrades Tvardi Therapeutics Inc (TVRD) to Overweight

Wed, 08 Jul 2026 15:38:54 -0400

Piper Sandler analyst Yasmeen Rahimi upgraded Tvardi Therapeutics Inc (NASDAQ: TVRD) from Neutral to Overweight with a price target of $13.00 (from $3.00).

For an analyst ratings summary and ratings history on Tvardi Therapeutics Inc click here. For more ratings news on Tvardi Therapeutics Inc click here.

Shares of Tvardi Therapeutics Inc closed at $3.10 yesterday.

Raymond James Upgrades Tvardi Therapeutics Inc (TVRD) to Outperform

Wed, 08 Jul 2026 03:47:58 -0400

Raymond James analyst Ryan Deschner upgraded Tvardi Therapeutics Inc (NASDAQ: TVRD) from Market Perform to Outperform with a price target of $10.00.

The analyst comments: “We are upgrading TVRD to Outperform after the recently reported Phase 1 dataset for STAT3 inhibitor prodrug, TTI-109, showed evidence of placebo-like GI tolerability, general bioequivalence with TTI-101 in terms of dose-proportional exposure above the IC50 of STAT3, and substantial reductions in humoral and cellular immune populations across the explored active dosing range. TVRD is now pivoting away from IPF to one or more target indications in the GI and dermatology spaces, which, pending additional funding,

Raymond James Upgrades Tvardi Therapeutics Inc (TVRD) to Outperform

Wed, 08 Jul 2026 03:47:58 -0400

Raymond James analyst Ryan Deschner upgraded Tvardi Therapeutics Inc (NASDAQ: TVRD) from Market Perform to Outperform with a price target of $10.00.

Form 8-K Tvardi Therapeutics, For: Jul 07

Tue, 07 Jul 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260707/26738249.html

Form 8-K Tvardi Therapeutics, For: Jul 07

Tue, 07 Jul 2026 07:03:00 -0400

si-local-file:///var/storage/secattach/20260707/26738249.html

Tvardi Therapeutics reports Phase 1 data for TTI-109 STAT3 inhibitor

Tue, 07 Jul 2026 07:00:33 -0400

Tvardi Therapeutics (NASDAQ: TVRD) announced Phase 1 results for TTI-109, its next-generation STAT3 inhibitor, showing the drug confirmed its prodrug design with improved tolerability compared to its predecessor compound TTI-101.

The study found TTI-109 rapidly converted to TTI-101 within two hours and produced nearly identical plasma levels at molar-equivalent doses. Over 21 days of repeat dosing, the drug showed stable, dose-proportional pharmacokinetics with concentrations above the STAT3 IC₅₀.

In an exploratory pharmacodynamic analysis, TTI-109 showed reductions of up to 60% in STAT3-driven immune cell populations, including Th17, T follicular helper and B cell subsets.

On tolerability, diarrhea events with TTI-109 were substantially shorter

Tvardi Therapeutics reports Phase 1 data for TTI-109 STAT3 inhibitor

Tue, 07 Jul 2026 07:00:33 -0400

In an exploratory pharmacodynamic analysis, TTI-109 showed reductions of up to 60% in STAT3-driven immune cell populations, including Th17, T follicular helper and B cell subsets.

On tolerability, diarrhea events with TTI-109 were substantially shorter

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Tue, 07 Jul 2026 07:00:00 -0400

TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and B cells

Company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal (GI) diseases - subject to additional funding

Company to host investor webcast today, July 7th, at 8:30am ET

HOUSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases,

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Tue, 07 Jul 2026 07:00:00 -0400

Company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal (GI) diseases - subject to additional funding

Company to host investor webcast today, July 7th, at 8:30am ET

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Tue, 07 Jul 2026 07:00:00 -0400

Company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal (GI) diseases - subject to additional funding

Company to host investor webcast today, July 7th, at 8:30am ET

Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Tue, 07 Jul 2026 07:00:00 -0400

Company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal (GI) diseases - subject to additional funding

Company to host investor webcast today, July 7th, at 8:30am ET

Form 4 Tvardi Therapeutics, For: Jun 09 Filed by: Shah Sujal